522-054

ID: compound_522_054

Aliases: 3-(2,5-difluorophenyl)-6-(N-ethylindol-5-yl)-1,2,4-triazolo[4,3-b]pyridazine

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• alpha7 nicotinic receptor PAM
• GABA-A alpha5 NAM

Optimization domains

• cognition
• schizophrenia
• attention

Research basis

• Studied as a dual-modulation approach for cognition and attention models.
• Preclinical behavioral and LTP data are the current basis.

Limits, risks, and missing evidence

• No mature human safety or efficacy package.
• Dual ion-channel modulation could carry seizure/anxiety/sleep risks that are not settled by rodent cognition tasks.

Risk flags

• preclinical only
• CNS
• seizure threshold unknown

Linked papers, labels, and reviews

1. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia
   review / pubmed_522054_2018_review
   Includes 522-054 as alpha7 nicotinic PAM plus GABA-A alpha5 NAM.
2. Allosteric modulation of related ligand-gated ion channels enhances cognition
   preclinical / pubmed_522054_ltp
   Mechanistic/preclinical 522-054 source.